Categories: CancerHealthcareNews

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.


To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13743023.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 10:00 a.m. ET on Friday, January 5, 2024, until 11:59 p.m. ET on Friday, January 12, 2024. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13743023.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Contacts

Investors:

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

Staff

Recent Posts

ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer

Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years…

60 minutes ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for…

4 hours ago

As Dangerous US Heat Wave Intensifies, AccuWeather Urges Public to Rely on Science-Backed RealFeel® Temperature for Accurate Danger Index

AccuWeather's RealFeel® Temperature is the only authentic formula-based metric—unlike 'Feels Like,' which lacks scientific credibility.Request…

4 hours ago

New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty

Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON,…

4 hours ago

Medmovie Hx Heart App Launch Elevates Health Literacy and Empowers Shared Decision Making for Cardiovascular Care

Digital tool equips healthcare providers with trusted visual content to simplify complex heart information at…

4 hours ago

Premera Blue Cross Blue Shield of Alaska Announces Actions to Simplify Prior Authorization Process

Blue Cross and Blue Shield companies aim to improve the prior authorization process to make…

4 hours ago